Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4

Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4

Single domain antibodies that combine antigen specificity with high tissue penetration are an attractive alternative to conventional antibodies. However, rapid clearance from the bloodstream owing to their small size can be a limitation of therapeutic single domain antibodies. Here, we describe and...

Full description

Bibliographic Details
Main Authors: Katherine Griffiths, Uli Binder, William McDowell, Rita Tommasi, Mark Frigerio, William G. Darby, Chris G. Hosking, Lionel Renaud, Matthias Machacek, Peter Lloyd, Arne Skerra, Michael Foley
Format: Article
Language:English
Published: Taylor & Francis Group 2019-10-01
Series:mAbs
Subjects:
Half-life extension
i-body
PA600
PEGylation
CXCR4
pharmacokinetics
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2019.1626652

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2019.1626652

Similar Items